-
Lancet: The effect of combination therapy in the treatment of diabetic peripheral neuropathy pain
Time of Update: 2022-09-06
OPTION-DM is a multicentre, randomized, double-blind, crossover trial in patients with DPNP with a mean daily Numerical Pain Score (NRS) of 4 or higher (on a scale of 0-10) from 13 UK centres .
-
The combination of the two immunotherapy combinations of Shishi Shiguibao has been approved by the FDA
Time of Update: 2021-03-03
BMS announced that the FDA has approved the PD-1 inhibitor Opdivo (nivolumab), in association with the CTLA-4 inhibitor Yeervoy (ipilimumab), to treat patients with hepatocellular carcinoma (HCC) who have previously received treatment with sorapinib.
-
Strong combination CD38 antibody/protease inhibitor combination therapy is FDA approved.
Time of Update: 2020-10-15
these two drugs are important representatives of protease inhibitors and CD38 antibody drugs respectively, both of which have been approved for the treatment of multiple myeloma.
CANDOR is the first randomized Phase 3 clinical trial to compare DKd with Kyprolis and Desemisson (Kd) combinations in R/R MM patients.
-
Leukemia: The combination of the drug quizatini in combination with dasatinyni may be effective in the treatment of acute myeloid leukemia.
Time of Update: 2020-08-28
Enzyme inhibitors, which close the replaceable survival path of cancer cells when they bind to another TKI called dasatinib, could be more effective in promoting leukemia cell death, and the results may help researchers develop new therapies to treat AML patients with the FRT3 gene mutation.
-
ASCO 2020: K-drug-combination lunvanini's "cola combination" re-emerges in renal transparent cell carcinoma
Time of Update: 2020-06-05
In Phase II clinical study Keynote-146, 104 patients with metastatic transparent cell renal cell carcinoma were treated Paboli-Zandi ( K drug) combined with lendatinib, also known as the cola comb
-
" combination of TheOpdivo and Yervoy combination of Time Squibb
Time of Update: 2020-06-03
CheckMate-040 is an ongoing open label, multi-queue study that is evaluating the efficacy and safety of Opdivo or Opdivo-based combination therapies in advanced HCC patients with or without viral hepa
-
Add a new proof – the combination of multiple blood biomarkers is expected to be an effective method for early identification of AD!
Time of Update: 2022-09-21
Last year, a cross-sectional study titled "Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer's Disease in South China"1 Blood biomarker levels, including Aβ42, Aβ40, t-tau, and neural filament light chain (NfL), were measured in 277 AD patients and 153 healthy controls with normal cognitive function from southern China to assess the efficacy of plasma biomarkers in diagnosing AD in populations in southern China.
-
ESMO Live Direct Strike Double Free or Triple? Choice of combination therapy regimens for Merkel cell carcinoma
Time of Update: 2022-09-21
The efficacy of navuliyumab + ipicumab ± stereotactic radiation (SBRT) in the treatment of advanced Merkel cell carcinoma was announced at the ESMO conference.
The efficacy of navuliyumab + ipicumab ± stereotactic radiation (SBRT) in the treatment of advanced Merkel cell carcinoma was announced at the ESMO conference.
-
The combination of yunnan baiyao and Huawei may play a catalytic role in the domestic AI drug research and development field
Time of Update: 2022-09-21
Tech Giants:Have laid out the AI pharmaceutical fieldAs the leading player of domestic artificial intelligence technology, Huawei has long had a layout in the AI-assisted drug research and development business.
-
Vandetanib in combination with everolimus for ACVR1 mutant diffuse pontine glioma
Time of Update: 2022-09-21
, of the Department of Molecular Pathology at cancer research institutes in London, UK, found that the VEGFR/RET/EGFR inhibitor Vandetanib reduces DIPG cell viability by targeting ACVR1 in vitro, but has limited ability to cross the blood-brain barrier.
-
The "Stone" Force Summit | a combination of Chinese and foreign countries, experts talk together, and explore the new direction of GIST treatment
Time of Update: 2022-09-21
The panel of experts held an online discussion>>>>Decisions on individualized GIST treatment plans that vary from person to personAvatinib has significant therapeutic activity against PDGFRA D842V mutant GIST, and Professor DeMatteo said that when Avatinib was applied to GIST neoadjuvant therapy, the intervention needed to be stopped 4 to 5 days before surgery due to the time required for drug clearance.
-
of the Celineso combination regimen has brought relief to MM patients involved in CNS!
Time of Update: 2022-09-21
At present, there is no standard treatment plan after CNS infiltration of MM, and the commonly used clinical treatment options include intrathecal injection, local radiotherapy, systemic chemotherapy and autologous stem cell transplantation1, however, the treatment effect is not ideal, and it is urgent to provide clinical benefits for some patients with high efficiency, low toxicity, and drugs that can cross the blood-brain barrier to directly hit the target.
-
DRCP: A comparative study of a combination of glimepiride/metformin fixation and monotherapy in patients with type 2 diabetes
Time of Update: 2022-09-20
Therefore, this clinical trial aims to evaluate and compare the efficacy and safety of glimepiride/metformin fixed-dose combinations (FDCs) and single high-dose glimepiride preparations with basal insulin in patients with type 2 diabetes.
-
ESMO 2022: Efficacy and safety of osbutinib in combination with R-CHOP in patients with previously untreated non-GCB DLBCL
Time of Update: 2022-09-20
Resources:2022 ESMO: 627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease
-
"Thiazolidinedione" in combination with second-line oral hypoglycemic therapy reduces the risk
Time of Update: 2022-09-20
Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study.
Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study.
